S&P 500   3,916.64
DOW   31,861.98
QQQ   305.80
Risk-Free Money Market vs. Bank Dividend Stock, Which is Better?
Buy THIS stock before Taiwan is attacked (Ad)
Deal for UBS to buy Credit Suisse sends shares tumbling
Gunmen kill 9 Chinese at mine in Central African Republic
Buy THIS stock before Taiwan is attacked (Ad)
Niinistö: Sweden security OK if Finland joins NATO first
The End of Coca Cola's Compressed Margins
Buy THIS stock before Taiwan is attacked (Ad)
Which Gold Stocks Can Help You Hedge Bank Exposure?
Enphase Energy is Still a Buy for Long-Term Growth Investors
S&P 500   3,916.64
DOW   31,861.98
QQQ   305.80
Risk-Free Money Market vs. Bank Dividend Stock, Which is Better?
Buy THIS stock before Taiwan is attacked (Ad)
Deal for UBS to buy Credit Suisse sends shares tumbling
Gunmen kill 9 Chinese at mine in Central African Republic
Buy THIS stock before Taiwan is attacked (Ad)
Niinistö: Sweden security OK if Finland joins NATO first
The End of Coca Cola's Compressed Margins
Buy THIS stock before Taiwan is attacked (Ad)
Which Gold Stocks Can Help You Hedge Bank Exposure?
Enphase Energy is Still a Buy for Long-Term Growth Investors
S&P 500   3,916.64
DOW   31,861.98
QQQ   305.80
Risk-Free Money Market vs. Bank Dividend Stock, Which is Better?
Buy THIS stock before Taiwan is attacked (Ad)
Deal for UBS to buy Credit Suisse sends shares tumbling
Gunmen kill 9 Chinese at mine in Central African Republic
Buy THIS stock before Taiwan is attacked (Ad)
Niinistö: Sweden security OK if Finland joins NATO first
The End of Coca Cola's Compressed Margins
Buy THIS stock before Taiwan is attacked (Ad)
Which Gold Stocks Can Help You Hedge Bank Exposure?
Enphase Energy is Still a Buy for Long-Term Growth Investors
S&P 500   3,916.64
DOW   31,861.98
QQQ   305.80
Risk-Free Money Market vs. Bank Dividend Stock, Which is Better?
Buy THIS stock before Taiwan is attacked (Ad)
Deal for UBS to buy Credit Suisse sends shares tumbling
Gunmen kill 9 Chinese at mine in Central African Republic
Buy THIS stock before Taiwan is attacked (Ad)
Niinistö: Sweden security OK if Finland joins NATO first
The End of Coca Cola's Compressed Margins
Buy THIS stock before Taiwan is attacked (Ad)
Which Gold Stocks Can Help You Hedge Bank Exposure?
Enphase Energy is Still a Buy for Long-Term Growth Investors
NASDAQ:ABEO

Abeona Therapeutics - ABEO Stock Forecast, Price & News

$2.39
-0.15 (-5.91%)
(As of 03/17/2023 06:55 PM ET)
Add
Compare
Today's Range
$2.35
$2.55
50-Day Range
$2.25
$3.27
52-Week Range
$2.19
$9.35
Volume
325,700 shs
Average Volume
207,881 shs
Market Capitalization
$41.06 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$22.00

Abeona Therapeutics MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
1,573.6% Upside
$40.00 Price Target
Short Interest
Healthy
2.78% of Float Sold Short
Dividend Strength
N/A
Sustainability
-1.03
Upright™ Environmental Score
News Sentiment
0.41mentions of Abeona Therapeutics in the last 14 days
Based on 6 Articles This Week
Insider Trading
Selling Shares
$2,385 Sold Last Quarter
Proj. Earnings Growth
N/A

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.25 out of 5 stars

Medical Sector

362nd out of 983 stocks

Pharmaceutical Preparations Industry

156th out of 480 stocks


ABEO stock logo

About Abeona Therapeutics (NASDAQ:ABEO) Stock

Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy products for severe and life-threatening rare diseases. The company's lead programs are EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A; and ABO-101, an adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome type B. It is also developing ABO-201 gene therapy for juvenile Batten disease; ABO-202 gene therapy for treatment of infantile Batten disease; EB-201 for for epidermolysis bullosa (EB); ABO-301 for Fanconi anemia disorder; and ABO-302 using a novel CRISPR/Cas9-based gene editing approach to gene therapy program for rare blood diseases. Further, it is involved in marketing MuGard, a mucoadhesive oral wound rinse for the management of mucositis, stomatitis, aphthous ulcers, and traumatic ulcers. Abeona Therapeutics Inc. has collaborations with EB Research Partnership and Epidermolysis Bullosa Medical Research Foundation that focus on gene therapy treatments for EB; and Brammer Bio for commercial translation of ABO-102. The company was formerly known as PlasmaTech Biopharmaceuticals, Inc. and changed its name to Abeona Therapeutics Inc. in June 2015. Abeona Therapeutics Inc. was incorporated in 1989 and is based in Dallas, Texas.

Receive ABEO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Abeona Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

ABEO Stock News Headlines

Abeona Therapeutics Inc (NASDAQ:ABEO) Short Interest Update
The gold catalyst we’ve waited for
If you thought the SVB meltdown was bad… watch out. Because even bigger red flag just appeared. This signal proves that a recession is likely right around the corner. It will take most by surprise. Stocks will crash. Millions will go jobless, and lose their homes. But there is ONE important step you should take today to make sure you come out the other side OK.
The gold catalyst we’ve waited for
If you thought the SVB meltdown was bad… watch out. Because even bigger red flag just appeared. This signal proves that a recession is likely right around the corner. It will take most by surprise. Stocks will crash. Millions will go jobless, and lose their homes. But there is ONE important step you should take today to make sure you come out the other side OK.
See More Headlines
Receive ABEO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Abeona Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

ABEO Company Calendar

Last Earnings
11/15/2021
Today
3/20/2023
Next Earnings (Estimated)
3/30/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:ABEO
Previous Symbol
OTCMKTS:ACCP
Employees
N/A
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$40.00
High Stock Price Forecast
$40.00
Low Stock Price Forecast
$40.00
Forecasted Upside/Downside
+820.5%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
2 Analysts

Profitability

Net Income
$-84,940,000.00
Pretax Margin
-1,961.64%

Debt

Sales & Book Value

Annual Sales
$3 million
Book Value
$8.73 per share

Miscellaneous

Free Float
16,764,000
Market Cap
$41.06 million
Optionable
Optionable
Beta
1.20

Key Executives

  • Mr. Steven H. Rouhandeh (Age 61)
    Exec. Chairman
  • Dr. Timothy J. Miller (Age 46)
    Pres, Chief Scientific Officer & Director
  • Mr. Jeffrey Blaine Davis (Age 55)
    Chief Operating Officer
  • Mr. Carsten Thiel (Age 54)
    Chief Exec. Officer
  • Mr. Stephen B. Thompson (Age 64)
    Sr. VP of Fin. and Admin., Chief Accounting Officer, Sec. & Treasurer













ABEO Stock - Frequently Asked Questions

Should I buy or sell Abeona Therapeutics stock right now?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Abeona Therapeutics in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" ABEO shares.
View ABEO analyst ratings
or view top-rated stocks.

What is Abeona Therapeutics' stock price forecast for 2023?

2 analysts have issued 1-year price objectives for Abeona Therapeutics' stock. Their ABEO share price forecasts range from $40.00 to $40.00. On average, they expect the company's share price to reach $40.00 in the next year. This suggests a possible upside of 1,573.6% from the stock's current price.
View analysts price targets for ABEO
or view top-rated stocks among Wall Street analysts.

How have ABEO shares performed in 2023?

Abeona Therapeutics' stock was trading at $3.08 at the start of the year. Since then, ABEO stock has decreased by 22.4% and is now trading at $2.39.
View the best growth stocks for 2023 here
.

Are investors shorting Abeona Therapeutics?

Abeona Therapeutics saw a increase in short interest during the month of February. As of February 28th, there was short interest totaling 460,500 shares, an increase of 6.7% from the February 13th total of 431,600 shares. Based on an average daily volume of 244,900 shares, the short-interest ratio is presently 1.9 days. Currently, 2.8% of the company's shares are short sold.
View Abeona Therapeutics' Short Interest
.

When is Abeona Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, March 30th 2023.
View our ABEO earnings forecast
.

How were Abeona Therapeutics' earnings last quarter?

Abeona Therapeutics Inc (NASDAQ:ABEO) issued its quarterly earnings data on Monday, November, 15th. The biopharmaceutical company reported ($4.00) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($4.00).

When did Abeona Therapeutics' stock split?

Abeona Therapeutics shares reverse split on the morning of Tuesday, July 5th 2022. The 1-25 reverse split was announced on Tuesday, July 5th 2022. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, July 5th 2022. An investor that had 100 shares of stock prior to the reverse split would have 4 shares after the split.

What other stocks do shareholders of Abeona Therapeutics own?
What is Abeona Therapeutics' stock symbol?

Abeona Therapeutics trades on the NASDAQ under the ticker symbol "ABEO."

Who are Abeona Therapeutics' major shareholders?

Abeona Therapeutics' stock is owned by a variety of institutional and retail investors. Top institutional investors include Point72 Asset Management L.P. (6.70%), Armistice Capital LLC (6.44%), EcoR1 Capital LLC (6.33%), AIGH Capital Management LLC (3.80%), Nantahala Capital Management LLC (1.59%) and Barclays PLC (1.08%). Insiders that own company stock include Brendan M O'malley, Edward Carr, Joseph Walter Vazzano, Mark Alvino, Michael Amoroso, Paul Elliot Mann, Sco Capital Partners Llc and Todd Wider.
View institutional ownership trends
.

How do I buy shares of Abeona Therapeutics?

Shares of ABEO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Abeona Therapeutics' stock price today?

One share of ABEO stock can currently be purchased for approximately $2.39.

How much money does Abeona Therapeutics make?

Abeona Therapeutics (NASDAQ:ABEO) has a market capitalization of $41.06 million and generates $3 million in revenue each year. The biopharmaceutical company earns $-84,940,000.00 in net income (profit) each year or ($18.31) on an earnings per share basis.

How can I contact Abeona Therapeutics?

Abeona Therapeutics' mailing address is 3333 LEE PARKWAY SUITE 600, DALLAS TX, 75219. The official website for the company is www.abeonatherapeutics.com. The biopharmaceutical company can be reached via phone at 214-665-9495, via email at ir@abeonatherapeutics.com, or via fax at 214-905-5101.

This page (NASDAQ:ABEO) was last updated on 3/20/2023 by MarketBeat.com Staff